Efficacy and Cost-Effectiveness of Dabigatran Etexilate Versus Warfarin in Atrial Fibrillation in Different Age Subgroups

This study aims to estimate the cost-effectiveness of dabigatran 150 mg twice daily versus warfarin for stroke and systemic embolism risk reduction in patients with nonvalvular atrial fibrillation initiating treatment before age 75 (

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2014-09, Vol.114 (6), p.849-855
Main Authors: Clemens, Andreas, MD, Peng, Siyang, MS, Brand, Sarah, BA, Brueckmann, Martina, MD, Kansal, Anuraag, PhD, Lim, Jonathan, MS, Noack, Herbert, PhD, Sander, Stephen, PharmD, Sorensen, Sonja, MPH
Format: Article
Language:English
Subjects:
Aged
Antithrombins - administration & dosage
Antithrombins - economics
Atrial Fibrillation - complications
Atrial Fibrillation - drug therapy
Atrial Fibrillation - economics
Benzimidazoles - administration & dosage
Benzimidazoles - economics
beta-Alanine - administration & dosage
beta-Alanine - analogs & derivatives
beta-Alanine - economics
Cardiac arrhythmia
Cardiovascular
Cost-Benefit Analysis
Dabigatran
Drug Administration Schedule
Drug Costs
Drug therapy
Female
Follow-Up Studies
Heart attacks
Hemorrhage
Humans
Incidence
Male
Medicare
Prognosis
Stroke
Thromboembolism - epidemiology
Thromboembolism - etiology
Thromboembolism - prevention & control
Time Factors
United States - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aims to estimate the cost-effectiveness of dabigatran 150 mg twice daily versus warfarin for stroke and systemic embolism risk reduction in patients with nonvalvular atrial fibrillation initiating treatment before age 75 (
ISSN:0002-9149
1879-1913
DOI:10.1016/j.amjcard.2014.06.015